At Avigen, we are developing the next generation of preclinical research and development services for immunotherapies, using our proprietary microfluidic platform. By assessing cellular avidity at high-throughput, we rapidly identify, sort, and isolate the most therapeutically valuable, target-specific cells from a broad pool of drug candidates.